Market capitalization | $43.52b |
Enterprise Value | $55.29b |
P/E (TTM) P/E ratio | 30.96 |
EV/FCF (TTM) EV/FCF | 30.26 |
EV/Sales (TTM) EV/Sales | 3.65 |
P/S ratio (TTM) P/S ratio | 2.87 |
P/B ratio (TTM) P/B ratio | 6.48 |
Revenue growth (TTM) Revenue growth | 3.45% |
Revenue (TTM) Revenue | $15.16b |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
27 Analysts have issued a IQVIA forecast:
27 Analysts have issued a IQVIA forecast:
Jun '24 |
+/-
%
|
||
Net Profit | 1,423 1,423 |
30%
30%
|
|
Depreciation and Amortization | 1,146 1,146 |
3%
3%
|
|
Stock Compensation | 196 196 |
20%
20%
|
|
Operating Cash Flow | 2,440 2,440 |
9%
9%
|
|
Investments | 613 613 |
7%
7%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | 1,827 1,827 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Provides biopharmaceutical development services and commercial outsourcing services
Head office | United States |
CEO | Ari Bousbib |
Employees | 87,000 |
Founded | 1950 |
Website | www.iqvia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.